LitAlert ~~

    • Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer.
    • Takano S, Fukasawa M, Shindo H, Takahashi E, Fukasawa Y, Kawakami S, Hayakawa H, Kuratomi N, Kadokura M, Yamaguchi T, Inoue T, Maekawa S, Enomoto N.
    • Cancer Sci. 2021 Dec 28. doi: 10.1111/cas.15249. Epub ahead of print.
    • Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients with Ovarian Cancer.
    • Weber-Lassalle K, Ernst C, Reuss A, Möllenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, Park-Simon TW, Hanker L, Prieske K, Schmidt S, Weber-Lassalle N, Pohl-Rescigno E, Kommoss S, Marmé F, Heitz F, Stingl JC, Schmutzler RK, Harter P, Hahnen E.
    • J Natl Cancer Inst. 2020 Dec 28:djab231. doi: 10.1093/jnci/djab231. Epub ahead of print.


    Untangling the Relationship between Clonal Hematopoiesis and Ovarian Cancer Therapies.

    • Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    • Perez JM, Twigg CAI, Guan W, Thomas SN.
    • J Am Soc Mass Spectrom. 2021 Dec 27. doi: 10.1021/jasms.1c00215. Epub ahead of print.
    • Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    • Eskiler GG, Ozturk M.
    • Cell Signal. 2021 Dec 24:110229. doi: 10.1016/j.cellsig.2021.110229. Epub ahead of print.
    • Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
    • Yordanova M, Hubert A, Hassan S.
    • Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.